Hemangiopericytoma
Symptoms, Doctors, Treatments, Advances & More

Hemangiopericytoma Overview

Save information for later
Sign Up

Learn About Hemangiopericytoma

View Main Condition: Brain Tumor

What is the definition of Hemangiopericytoma?
Hemangiopericytoma is a term used to described a group of tumors that are derived from pericytes, the cells normally arranged along specific types of blood vessels called capillaries and venules. These types of tumors are typically slow-growing, may be either benign (non-cancerous) or malignant (cancerous), and may occur anywhere in the body.
What are the alternative names for Hemangiopericytoma?
  • Hemangiopericytoma
Who are the top Hemangiopericytoma Local Doctors?
Advanced in Hemangiopericytoma
Dr. Edward J. Bieber
Hand Surgery | Orthopedics | Sports Medicine
Advanced in Hemangiopericytoma
Dr. Edward J. Bieber
Hand Surgery | Orthopedics | Sports Medicine
Referral may be required
Before you request

OrthoBethesda

10215 Fernwood Road, Suite 506, 
Bethesda, MD 
301-530-1010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Bieber is an Orthopedics specialist and a Sports Medicine provider practicing medicine in Bethesda, Maryland. Dr. Bieber is rated as an Advanced provider by MediFind in the treatment of Hemangiopericytoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Synovitis, Tendinitis, Tenosynovitis, and Trigger Thumb. Dr. Bieber is board certified in Abos.

Elite in Hemangiopericytoma
Elite in Hemangiopericytoma
Referral may be required
No.1 XinSi Road, 
Xi'an, CN 

Yingxi Wu practices practicing medicine in Xi'an, China. Wu is rated as an Elite expert by MediFind in the treatment of Hemangiopericytoma. They are also highly rated in 4 other conditions, according to our data. Their clinical expertise encompasses Hemangiopericytoma, Brain Herniation, Schwannoma, Acoustic Neuroma, and Oophorectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Hemangiopericytoma
Distinguished in Hemangiopericytoma
Referral may be required

CUIMC/Neurological Institute Of New York

710 W 168th St, 
New York, NY 
347-380-6061
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Bruce is a Neurosurgery provider practicing medicine in New York, New York. Dr. Bruce is rated as a Distinguished provider by MediFind in the treatment of Hemangiopericytoma. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Gamma Knife Radiosurgery, and Awake Craniotomy. Dr. Bruce is currently accepting new patients.

View All Doctors
What are the latest Hemangiopericytoma Clinical Trials?
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Other

Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Enrollment Status: Recruiting
Publish Date: November 26, 2024
Intervention Type: Other

Summary: The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center